These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34787787)

  • 21. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

  • 23. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
    Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
    Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.
    Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M;
    Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m
    O'Kane CP; Avalon JCO; Lacoste JL; Fang W; Bianco CM; Davisson L; Piechowski KL
    Pharmacotherapy; 2022 Feb; 42(2):112-118. PubMed ID: 34820876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor-Associated Bleeding: A Retrospective Study.
    Wilsey HA; Bailey AM; Schadler A; Davis GA; Nestor M; Pandya K
    J Intensive Care Med; 2021 May; 36(5):597-603. PubMed ID: 32242482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activated Prothrombin Complex Concentrate versus Plasma for Reversal of Warfarin-Associated Hemorrhage.
    Rowe AS; Mahbubani PS; Bucklin MH; Clark CT; Hamilton LA
    Pharmacotherapy; 2016 Nov; 36(11):1132-1137. PubMed ID: 27726162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Fixed Versus Weight-Based Prothrombin Complex Concentrate Dosing Strategies for Factor Xa Inhibitor Reversal.
    Brett S; Taylor M; Pamela M; Michael G
    Clin Appl Thromb Hemost; 2024; 30():10760296241243368. PubMed ID: 38710155
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor VIII Inhibitor Bypassing Activity (FEIBA) Reversal for Apixaban and Rivaroxaban in Patients With Acute Intracranial and Nonintracranial Hemorrhage.
    Hunt AR; Coffeen SN; Shiltz DL; Ice C; Parker J
    Ann Pharmacother; 2021 Dec; 55(12):1455-1466. PubMed ID: 33843267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system.
    Jakowenko N; Nguyen S; Ruegger M; Dinh A; Salazar E; Donahue KR
    Thromb Res; 2020 Dec; 196():276-282. PubMed ID: 32947066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
    Maragkos GA; Nelton EB; Richter S; Stippler M
    World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of apixaban and rivaroxaban in obese patients with acute venous thrombosis/embolism.
    Anusim N; Ghimire B; Smalley M; Jaiyesimi I; Gaikazian S
    Eur J Haematol; 2022 Oct; 109(4):409-412. PubMed ID: 35739626
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
    Ruff CT; Giugliano RP; Antman EM
    Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
    Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
    J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.